Funded Biotechnology Startups in Israel
Among the 50 most recent biotechnology funding entries in Israel, the largest disclosed round is InSightec’s $150M (2024-06-18).
Among the 50 most recent biotechnology funding entries in Israel, the largest disclosed round is InSightec’s $150M (2024-06-18). That figure dwarfs the rest of the disclosed rounds, where several large financings cluster far below it (for example, CytoReason’s $80M on 2024-07-17, Enlivex Therapeutics’ $212M on 2025-11-24, and MitrAssist’s $100M on 2023-09-26), while many entries sit in the $3M–$25M band (e.g., Magdent at $150K on 2026-06-24; Collplant at $3M on 2026-06-30). A notable geography cluster shows up in Tel Aviv and the broader Tel Aviv area: multiple rounds cite Tel Aviv, Tel Aviv-Yafo, or nearby cities (e.g., Splisense in Jerusalem on 2026-06-16; BlueWind Medical in Herzliya on 2026-05-14; RedHill Biopharma in Tel Aviv on 2026-06-18). Temporally, the listing’s newest disclosed entry is Collplant on 2026-06-30, while the oldest row is MitrAssist on 2023-09-26, spanning nearly three years.
Stage classification is frequently missing: 31 of the 50 rows are labeled “Series Unknown,” and 2 are “undisclosed” (Renewal Bio on 2025-11-11; CannaSoul Analytics on 2025-11-03). When stages are specified, the mix is led by one-off but repeated denominations such as “Series A” (e.g., SuperMeat at $6M on 2026-05-12; Starget Pharma at $18M on 2026-02-18; Vessi Medical at $17M on 2024-02-14), alongside occasional larger late-stage prints like Omnix Medical’s Series C at $25M (2025-10-15) and MitrAssist’s Series C at $100M (2023-09-26).
Most recent rounds
50 of 8636 more funded startups
This page shows the 50 most recent rounds (back to Sep 2023). The full 86-company history for this listing is available on a paid plan.
Unlock all 86 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What’s the largest disclosed funding round in this Israel biotech list, and how far above the next-largest disclosed rounds is it?
The largest disclosed round is Enlivex Therapeutics’ $212M on 2025-11-24. The next-largest disclosed entries include MitrAssist’s $100M (2023-09-26) and InSightec’s $150M (2024-06-18), placing Enlivex above even the biggest financings visible in this table.
Which entries appear at the extreme low end of disclosed amounts, and how does that compare to typical deal sizes shown?
The smallest disclosed amount is Magdent’s $150K on 2026-06-24, with another very small disclosed round NurExone Biologic at $560K on 2025-08-20. By contrast, many disclosed rounds cluster in the mid-single to mid-double digits of millions (for example, Collplant at $3M on 2026-06-30, and Phytolon at $24M on 2026-05-26).
How concentrated are the most recent rounds in time, and what does the date edge tell an analyst?
The newest row is Collplant on 2026-06-30 ($3M), and multiple entries fall in late June 2026 (e.g., Magdent on 2026-06-24 at $150K; RedHill Biopharma on 2026-06-18 at $6M; Splisense on 2026-06-16 at $13M). The oldest entry in the 50-row window is MitrAssist on 2023-09-26 ($100M), creating a wide historical span rather than a short burst.
Are there stage labeling patterns that affect how many rounds can be compared by stage?
Stage is frequently not specified: 31 of 50 rows are “Series Unknown,” and 2 are “undisclosed” (Renewal Bio on 2025-11-11; CannaSoul Analytics on 2025-11-03). That means most comparisons should be made by disclosed amount/date rather than stage, even when “Series A,” “Series B,” or “Series C” appear (e.g., CytoReason Series B at $80M on 2024-07-17; Omnix Medical Series C at $25M on 2025-10-15).
Do any cities cluster tightly across entries, especially around the Tel Aviv area?
Yes, the list repeatedly references Tel Aviv or Tel Aviv-adjacent municipalities: multiple entries cite Tel Aviv/ Tel Aviv-Yafo (e.g., RedHill Biopharma in Tel Aviv on 2026-06-18 for $6M; Lutris Pharma in Tel Aviv-yafo on 2025-01-28 for $30M; CytoReason in Tel Aviv on 2024-07-17 for $80M). Several other nearby cities—Herzliya, Ness Ziona, and Tirat Carmel—also recur (e.g., BlueWind Medical in Herzliya on 2026-05-14 for $48M; Enlivex Therapeutics in Ness Ziona on 2025-11-24 for $212M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.